Molecular profiling to optimize treatment in non-small cell lung cancer: A review of potential molecular targets for radiation therapy by the translational research program of the Radiation Therapy Oncology Group

Natalie L. Ausborn, Quynh Thu Le, Jeffrey D. Bradley, Hak Choy, Adam P. Dicker, Debabrata Saha, Jeff Simko, Michael D. Story, Artour Torossian, Bo Lu

    Research output: Contribution to journalReview articlepeer-review

    33 Scopus citations

    Abstract

    Therapeutic decisions in non-small cell lung cancer (NSCLC) have been mainly based on disease stage, performance status, and co-morbidities, and rarely on histological or molecular classification. Rather than applying broad treatments to unselected patients that may result in survival increase of only weeks to months, research efforts should be, and are being, focused on identifying predictive markers for molecularly targeted therapy and determining genomic signatures that predict survival and response to specific therapies. The availability of such targeted biologics requires their use to be matched to tumors of corresponding molecular vulnerability for maximum efficacy. Molecular markers such as epidermal growth factor receptor (EGFR), K-ras, vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), and anaplastic lymphoma kinase (ALK) represent potential parameters guide treatment decisions. Ultimately, identifying patients who will respond to specific therapies will allow optimal efficacy with minimal toxicity, which will result in more judicious and effective application of expensive targeted therapy as the new paradigm of personalized medicine develops.

    Original languageEnglish
    Pages (from-to)e453-e464
    JournalInternational Journal of Radiation Oncology Biology Physics
    Volume83
    Issue number4
    DOIs
    StatePublished - Jul 15 2012

    Keywords

    • Chemotherapy
    • Genomic signatures
    • Molecular markers
    • Non-small cell lung cancer
    • Radiation therapy

    Fingerprint

    Dive into the research topics of 'Molecular profiling to optimize treatment in non-small cell lung cancer: A review of potential molecular targets for radiation therapy by the translational research program of the Radiation Therapy Oncology Group'. Together they form a unique fingerprint.

    Cite this